Insulin formulation
US5534488A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Aug 13, 1993 |
| Grant date | Jul 9, 1996 |
| Priority date | — |
| Expiry date | Aug 13, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to an insulin formulation comprising a suspension of Ultralente crystals and a total formulation zinc concentration of between about 0.5 milligrams to about 20 milligrams per 100 units of insulin. Greater than fifty percent of the total zinc in the formulation resides in the soluble fraction, rather than in complex with the insulin. This insulin formulation generally has a pH from between about 6.0 to about 7.4. In addition, the insulin formulation of the present invention does not contain other proteins like protamine. This zinc-modified formulation displays characteristics of a very long lasting human insulin product.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.